Objective To determine the prevalence, spectrum, and prognostic significance of copy number variants of undetermined significance (cnVUS) seen on chromosomal microarray (CMA) in neonates with hypoplastic left heart syndrome (HLHS).
D
espite the significant advances in surgical palliation and medical management over the past 4 decades, hypoplastic left heart syndrome (HLHS) still carries significant morbidity and mortality. [1] [2] [3] The backbone of palliation is the 3-stage surgical intervention comprising the Norwood, Glenn, and Fontan procedures. Even with major centers achieving survival rates to discharge of up to 90% following the Norwood procedure, these neonates remain at a high risk of death before the Glenn procedure. 4 This so-called "interstage mortality" can be as high as 24% in children with HLHS. 5 At Texas Children's Hospital (TCH), interstage mortality was 12% from 2002 to 2007, before the single-ventricle program was established, and 8% from 2007 to 2010, with a 12.5% overall hospital discharge mortality following the Norwood procedure in 2013 to 2016. 6, 7 Several clinical factors have been associated with increased mortality, including prematurity, low birth weight, pulmonary venous obstruction, restrictive or intact atrial septum, performance of the Norwood procedure in children aged >1 month, and genetic syndrome-associated copy number variation (CNV). [8] [9] [10] [11] [12] Given the prognostic relevance and high prevalence of CNVs, genetic testing by chromosomal microarray (CMA) has become routine and a standard of care. 13, 14 CMA is a genome-wide screening technique used to detect chromosomal imbalances. 13 As CMA testing in neonates with HLHS has increased, so has the detection of copy number variants of unknown/ undetermined significance (cnVUS). 13 The uncertainty inherent in these findings impairs the ability to adequately predict the potential for morbidity and mortality, with consequences for provider management strategies and appropriate counseling of families. To this end, we sought to determine the spectrum, prevalence, and diagnostic relevance of cnVUSs in neonates with HLHS.
In this study, we evaluated the association between CMA results and morbidity and mortality in patients with HLHS to determine the potential prognostic implications of cnVUS results.
Methods
In this Institutional Review Board-approved study, we conducted a retrospective review of all neonates diagnosed with HLHS at TCH between June 2008 and December 2016. Inclusion criteria were neonates with HLHS who presented to TCH within 30 days of birth and underwent CMA testing through the Baylor Genetics Laboratories (previously Baylor College of Medicine Medical Genetics Laboratories). Exclusion criteria were receipt of a palliative surgical procedure at another center before transfer, and single-ventricle lesions not clearly defined as HLHS, including unbalanced atrioventricular septal defects and double-outlet right ventricle. Data collected included patient sex, race/ethnicity, age at presentation, gestational age at birth, birth weight, atrial level restriction, echocardiographic characteristics, and CMA testing results. Echocardiograms were analyzed to determine the presence of mitral stenosis (MS)/aortic stenosis (AS), MS/aortic atresia (AA), mitral atresia (MA)/AA, left superior vena cava, total anomalous pulmonary venous return/anomalous pulmonary venous return, degree of tricuspid regurgitation, diameter of the ascending aorta, and degree of right ventricular dysfunction.
The patients were studied using V7, V8, V9, V10, and V11 arrays designed by Baylor Medical Genetics Laboratories and manufactured by Agilent Technologies (Santa Clara, California). The V7 array included approximately 105 000 interrogating oligonucleotides selected from Agilent's online library (eArray; https://earray.chem.agilent.com/earray/), with backbone coverage of~30 kb. 15, 16 The V8 array included~180 000 oligonucleotides targeting~1714 genes plus 101 644 probes used for single nucleotide polymorphism analysis for the detection of uniparental disomy and absence of heterozygosity. 16 The V9, V10, and V11 arrays targeted more than 4800 genes with oligonucleotides including those at the exon level and had an average of >4.2 probes per exon for single nucleotide polymorphism analysis. 17 Further details are available at https://www.bcm.edu/geneticlabs/.
We defined structural variation in the genome as variants involving more than 50 base pairs. Our patient cohort was compared with CNV data from a stringent database of CNVs that was later compiled as the Database for Genomic Variants genome browser, a database of structural variants of the human genome in healthy patient cohorts. 18 This database included 72 studies to create a reference cohort including 2 057 386 variants among 2647 subjects across diverse ethnicities with identified structural variations in the genome. 18 Each CNV locus labeled as a cnVUS was compared with the healthy reference cohort to discern the frequency of healthy CNV seen at each cnVUS locus. The stringent map variants were used to determine control cohort frequency.
The primary outcome studied was overall survival. Secondary outcomes included tracheostomy, nasogastric or gastrostomy tube placement at discharge from initial hospitalization, cardiopulmonary resuscitation, and extracorporeal membrane oxygenation (ECMO).
Statistical Analyses
Continuous variables are presented as mean with SD and median with IQR. One-way ANOVA or the Kruskal-Wallis test was applied to compare differences among the 3 groups for data with a normal or nonnormal distribution, respectively. Categorical variables are expressed as counts with percentages, and proportions were compared using the Fisher exact test. Survival was compared using Kaplan-Meier analysis, with comparisons by the log-rank test, with birth as time 0 and censoring at death or the last follow-up. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, North Carolina).
Results
Given the broad use of CMAs as a diagnostic tool in children with a variety of underlying diseases, we first sought to determine the overall prevalence of abnormal and cnVUS findings in pediatric patients seen at TCH regardless of diagnosis. We identified a total of 6410 CMAs performed in individual subjects. Among these CMAs, 4089 (63.2%) were interpreted as "normal," 1692 (26.2%) as cnVUSs, and 689 (10.6%) as abnormal genetic test results associated with a known genetic syndrome (Figure 1 ; available at www.jpeds.com). This suggests that a considerable proportion of CMA results, which were cnVUS, did not provide any clear diagnostic utility for clinicians.
A total of 105 infants, including 60 males (57%) and 45 females (43%), met our inclusion criteria. The median age of presentation in all groups was the first day of life. These findings, along with birth weight, gestational age, and frontooccipital circumference, are summarized in Table I (available at www.jpeds.com). CMAs performed on these children demonstrated no CNV abnormality in 70 (66.7%), a cnVUS in 26 (24.7%), and a CNV interpreted as syndromic/pathological in 9 (8.6%) (Table II; available at www.jpeds.com). The pathological CNVs identified in patients with HLHS were associated with several medically relevant phenotypes, including Turner syndrome (n = 4; 67% of abnormal females) and Pallister-Killian syndrome (n = 1). In addition, pathological CNV was associated with gastrointestinal dysmotility and renal and craniofacial abnormalities. Although diverse loci were affected, 4 chromosomal rearrangements occurred on the X chromosome. The CNVs were due to both copy number losses (50%) and copy number gains (50%). These findings are summarized in Table III (available at www.jpeds.com). In Volume 202 • November 2018 comparison, CNVs interpreted as cnVUSs were due to copy number gain (59%), copy number loss (37%), and absence of heterozygosity (4%) and were highly variable in location. These findings are summarized in Table IV (available at www.jpeds.com).
To determine whether HLHS-associated cnVUSs were associated with variation seen in ostensibly healthy individuals, we cross-referenced them with a stringent meta-database of CNV seen in healthy individuals, published in Nature Reviews Genetics. 18 This database compiled information on CNVs considered healthy "background" genetic variations. Six of the 26 (23.0%) cnVUS probands with HLHS had a variant that localized to a specific region of the genome identified among the healthy cohort CNV. The remaining 20 (77.0%) had a CNV not included in the healthy reference population. In addition, only 2 of these 6 patients with HLHS had loci involved in >1% of the healthy patient cohort, including the 9p21.3 gain cnVUS, which was seen in 12.9% of the cohort, and 15q11.2 loss, which was seen in 4.16%. These results are summarized in Table V (available at www.jpeds.com). Overall, these findings suggest that cnVUSs do not clearly represent healthy "background" genetic variation and may be a distinct genetic subset of children with HLHS.
To evaluate the possibility that the remaining cnVUSs not seen in otherwise healthy individuals may involve clinically relevant genes, we mapped each against a comprehensive list of 935 clinically relevant genes known to involve CNVs. 18 Only a small minority of cnVUS-positive subjects were found to host genes associated with genetic diseases (Table VI) . Of the remaining 20 subjects who did not have CNV in the healthy population, only 5 cnVUSs involved loci containing genes in which single gene mutations or CNV are associated with predisposition to disease. Overall, these genes were associated with developmental delay, autism spectrum disorders, craniofacial abnormalities, macrocephaly, and epilepsy. A single cvVUS was associated with congenital heart disease (CHD) and arrhythmias. The cnVUS with a gain in 1q21.1 contains GJA5, which encodes a gap junction protein, alpha 5 (connexin 40), and has been associated with the development of atrial fibrillation, atrial standstill, and cardiac malformations.
The 1-year Kaplan-Meier survival was 68.3% in patients with a normal CMA, 84.0% in those with cnVUS, and 33.3% in those with pathological CNV (P = .003, log-rank test). Survival by Kaplan-Meier analysis is illustrated in Figure 2 . We noted a significantly higher prevalence of extracardiac abnormalities in infants with HLHS with abnormal CMAs (55.6%) compared with infants with normal (5.7%) and cnVUS (8%) CMA results (P < .001).
Right ventricular dysfunction was also more common in the abnormal CMA group (22.2%) compared with the cnVUS (7.7%) and normal (5.7%) groups (P = .016). There were no significant differences in the HLHS morphological variation based on CMA class result, including prevalence of MS/AS, MS/ AA, or MA/AA; presence of a left superior vena cava; degree of tricuspid regurgitation; levocardinal vein; abnormal coronary arteries; ascending aorta diameter; and anomalous pulmonary venous return (Table VII) .
Given the differences in survival based on CMA groups, we next evaluated a number of secondary endpoints by CMA class. We identified no significant differences in the use of tracheostomy, feeding tube, or cardiopulmonary resuscitation based on CMA class (P = 1.00, 1.00, and .139, respectively; Table VIII) . Of note, ECMO was not used in probands with either cnVUS or pathological CMA findings, but 11 probands with normal CMAs required ECMO (15.7%) (P = .038).
Discussion
CNVs, or unbalanced chromosomal rearrangements, have a wide array of clinical associations. Although there is a broad spectrum of syndromic CNVs, HLHS probands hosting this class of CMA have a worse prognosis compared with their normal counterparts. Multiple studies have found that chromosomal abnormalities and genetic syndromes negatively impact interstage mortality. One study found that the 1-year and 10-year survival in patients with HLHS and a pathological genetic syndrome was one-half that in those with a normal genetic profile. 3, 12, 19, 20 Among other known syndromes, Turner syndrome, trisomy 18, trisomy 13, and Down syndrome are associated with higher early mortality in HLHS. 21, 22 One study reported 50% 1-month survival in patients with HLHS with Turner syndrome, as opposed to 85% in nonsyndromic patients with HLHS, 23 and another study found significantly increased cumulative mortality compared with females without Turner syndrome, even with multivariate analysis controlling for low birth weight. 24 Another study demonstrated a 5-year survival of 61% in patients with Down syndrome, compared with 85% in nonsyndromic patients. 25 Therefore, an abnormal result detected on CMA is widely considered a predictor of increased mortality in CHD. However, with the rapidly expanding use of clinical CMA, which is becoming the gold standard for neonates with HLHS, there is increasing awareness of cnVUS. With 26.2% of all children at our institution referred for CMA testing and 20% of patients with HLHS having a cnVUS result, this is a common issue that likely will increase in importance with the expanding use of genetic testing.
The general consensus among most studies is that the prevalence of chromosomal anomalies in CHD is higher when extracardiac anomalies are also present. 26 Thus, both genetic syndromes and extracardiac anomalies, as individual and combined factors, are associated with heightened mortality. 20, 27 However, our patients with cnVUS results did not exhibit the same characteristics as their abnormal counterparts, achieving significantly higher survival rates with a significantly lower prevalence of extracardiac abnormalities.
To evaluate the genetic significance of observed cnVUS results, we compared results with loci identified in healthy individuals and determined whether there was any overlap with loci of clinically actionable genes. Studies exploring incidentally identified VUSs associated with cardiomyopathies and channelopathies have suggested that the majority of these variants are likely background genetic noise. 28 When comparing the cnVUS cohort with ostensibly healthy individuals, fewer than one-quarter of our patients had the same loci identified in the healthy individuals. As such, we cannot assume that cnVUS results are comparable between patients with HLHS and healthy individuals; rather, they appear to be genetically distinct. Of the remaining CNVs not included in the crossreferenced database, 5 had clinically actionable genes involved. Among these, GJA5 has been associated with cardiac disease. Importantly, polymorphisms of GJA5 detected in families with cases of atrial standstill were clinically manifested only if coinherited with mutations in the SCN5A gene. 29, 30 Furthermore, clinical manifestations of atrial fibrillation were associated with rare, novel missense and nonsense mutations. [31] [32] [33] [34] Mouse models with limited or absent expression of GJA5 have demonstrated a higher prevalence of cardiac anomalies, usually of conotruncal origin, with one-third of hearts exhibiting 35 Although most of these genes have little immediate clinical impact on survival in patients with HLHS, they may have an impact on patient long-term morbidity that is difficult to determine. Aside from this single cnVUS, associated phenotypes with the other clinically actionable genes include mainly longterm neurobehavioral/psychiatric conditions. These conditions are often associated with significant functional limitations in executive planning, visual-motor integration, and thought processing. 36 Nonetheless, although genetics play a role, neurobehavioral limitations are usually due to a variety of factors, including parental IQ, cardiopulmonary bypass conduct, hemodynamic instability, intraoperative procedures, and perioperative neuroprotection. [36] [37] [38] Ultimately, cnVUS results were not commonly found in ostensibly healthy individuals, and loci did not commonly contain clinically significant genes, suggesting that cnVUSs represent a distinct genetic subclass within HLHS, and that there does not appear to be a genetic explanation for the survival seen in individuals with cnVUSs.
Our finding that patients with HLHS with cnVUSs have superior survival to their syndromic counterparts suggests that the worse prognosis associated with abnormal CMA is restricted to known genetic syndromes. Although we identified a statistically significant greater number of neonates with normal CMAs who received ECMO support compared with patients with cnVUS and abnormal CMA findings, given our study methodology, we cannot definitively conclude that the genetic test results altered patient management. The decision to initiate ECMO support is a multifaceted process. Previous studies have noted the inclusion of known pathological mutations as part of end-of-life care discussions with the families of patients, and clinical management has the potential to be influenced by the presence of abnormal CMA. 39, 40 We recognize the limitations of our small sample size and the fact that CMA testing of infants with HLHS is not universal. Thus, estimates of CNVs could be amplified in our patient cohort. A better understanding of the effects of cnVUS results on physician/patient family decision making is needed.
We find that cnVUS are common among children who receive CMAs and among children with HLHS. Although CNV associated with known genetic syndromes carries a negative prognostic association, we find cnVUS-associated survival to be equal, and perhaps superior to, normal CMA class. ■ Submitted for publication Apr 23, 2018 
